Project Grant P01CA288662
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$2.2M
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396) provides $359,138 to the University of California, Irvine (UC Irvine) to conduct research on the mechanisms of treatment-free remission in a mouse model of chronic myeloid leukemia (CML). The goal is to understand the biological processes that enable some CML patients to stop tyrosine kinase inhibitor therapy and maintain low or undetectable levels of leukemic cells, a...
This $590,625 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to develop a novel therapeutic strategy targeting mutant p53, a key driver of tumor progression and therapy resistance in more than half of human cancers. The principal investigator at the University of California, Davis (UC Davis) will:
Determine how mutant p53 expression is regulated by the CDK4/6-RBM38-eIF4G axis and the role of mutant...
The National Cancer Institute (NCI) awarded a $676,584 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The University of Texas MD Anderson Cancer Center. The 5-year grant, which began on April 1, 2025, will support research to investigate the co-evolution of cancer cell genomic alterations and their interactions with the tumor microenvironment during metastatic spread of triple-negative breast cancer (TNBC) to multiple organ sites.
The research project aims to...
This $754,511 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at The Jackson Laboratory to discover host genetic factors that affect response to immune checkpoint inhibitor (ICI) cancer therapies.
The project aims to map quantitative trait loci (QTLs) in mice that influence ICI response, test the top candidate genes, and expand the QTL mapping to additional mouse tumor models. The goal is to identify new...
This National Cancer Institute (NCI) Project Grant award under the Cancer Biology Research program (CFDA 93.396) provides $444,952 in funding to the University of California, San Diego (UCSD) to explore the impact of base deaminase deregulation on the evolution of precancerous cells to acute myeloid leukemia.
The primary objective is to elucidate the relative roles of the APOBEC3C and ADAR1 base deaminases in driving the transformation of pre-leukemic stem cells (pre-LSCs) to leukemic stem...
The National Cancer Institute (NCI) awarded a $619,628 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The funding will support the development and validation of an autologous mouse model to study immune system interactions with glioblastoma, a type of brain cancer. The goal is to create a humanized mouse system that incorporates patient-derived...
The National Cancer Institute (NCI) awarded a $1,217,906 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Cosmyc Inc. of Dover, DE. The grant, with a funding period from June 18, 2024 to May 31, 2025, will support research into the therapeutic inhibition of the MYC:TRRAP interaction in cancer. This fundamental cancer biology research aims to provide critical insights into the molecular and cellular mechanisms underlying cancer development and progression, with the...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to evaluate the congruence and selection of cancer models, such as cell lines, patient-derived xenografts, and organoids, towards enabling precision cancer research and translational applications. The $585,931 grant will fund a 5-year project that aims to: 1) identify and clinically annotate prevalent subclones and tumor microenvironment cell types in breast cancer, 2)...
This $501,606 federal Project Grant award, funded by the National Cancer Institute under its Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to develop and characterize a microphysiological system (MPS) platform for modeling peritoneal carcinomatosis (PC), which is a deadly form of metastatic colorectal and gastric cancer. The University of California, Irvine (UC Irvine) will pursue three key objectives: 1) characterize a dual-tissue platform that models PC, 2) correlate...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $1,343,188 in funding to The Regents of the University of California, San Francisco to conduct research aimed at understanding the molecular and cellular mechanisms underlying the development of drug resistance in squamous cell carcinomas.
The key objectives of this 5-year research project are to: 1) Use single-cell analyses to identify tumor cell populations with high...